Login to Your Account

Zalicus Shifts Gears to Pain After Phase IIb Miss in RA

By Catherine Shaffer
Staff Writer

Monday, September 10, 2012

Zalicus Inc., of Cambridge, Mass., is immediately terminating its development program for Synavive after a Phase IIb trial in rheumatoid arthritis failed to show meaningful clinical benefit compared to prednisolone, the active glucocorticoid component of the drug.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription